GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma

Inclusion Criteria:

• Subjects must have confirmed diagnosis of aHCC (locally advanced or metastatichepatocellular carcinoma) by radiography, histology and/or cytology, not eligible forsurgical and/or locoregional therapies; or progressive disease after surgical and/orlocoregional therapies (fibrolamellar, sarcomatoid HCC and mixed hepatocellular /cholangiocarcinoma subtypes are not eligible);
• Have Barcelona Clinic Liver Cancer (BCLC) Stage C disease or BCLC Stage B disease notamenable to locoregional therapy or refractory to locoregional therapy;
• Have documented disease progression after or intolerance to first line treatment ofimmune checkpoint inhibitors(ICI)
• Child-Pugh score ≤ 6 (Child-Pugh A) score within 7 days of first dose of study drug;
• ECOG performance status: 0-1 within 7 days of first dose of study drug;
• Have a predicted life expectancy of greater than 3 months;
• Adequate hematologic and end-organ function functions of the important organs areconfirmed.

Exclusion Criteria:

• Presence of tumor thrombus involving main trunk of portal vein (Vp4), inferior venacava, cardiac involvement of HCC;
• Subjects with untreated or incompletely treated varices with bleeding or high-risk forbleeding. Has had esophageal or gastric variceal bleeding within the last 6 months;
• History of encephalopathy;
• Has a known history of, or any evidence of central nervous system (CNS) metastasesand/or carcinomatous meningitis;
• Had history of a solid organ or hematologic transplant;
• Has received locoregional therapy to liver (TACE, TAE, hepatic arterial infusion [HAI], radiation, radioembolization or ablation) within 4 weeks of start of studytreatment.
• Had prior systemic TKI treatment prior to start of study treatment;
• Has received prior immune checkpoint inhibitors within 4 weeks of start of studytreatment;
• Has received Nivolumab in the first-line systemic therapy:
• Active co-infection with:

1. Both hepatitis B and C as evidenced by positive HBV surface antigen or detectableHBV DNA and HCV RNA, OR
2. Hepatitis D infection in subjects with hepatitis B

• Has an active bacterial or fungal infection requiring systemic therapy within 7 daysprior to study drug dosing;
• Has a known history of active tuberculosis (Bacillus Tuberculosis);
• Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture;
• Thrombotic or embolic events (except HCC tumor thrombus) within the past 6 months,such as cerebrovascular accident (including transient ischemic attacks), pulmonaryembolism; If prior history of deep vein thrombosis (DVT) / (pulmonary embolism (PE),the subject needs to be on stable doses of anticoagulation with low molecular weightheparin or oral anticoagulant for at least two weeks;
• Has a known additional malignancy that is progressing or has required active treatmentwithin the past 3 years.
• Has a history of (non-infectious) pneumonitis that required steroids or has currentpneumonitis;
• Subjects with any other serious disease considered by the investigator not in thecondition to enter into the trial;